Regis Management Co adds Glaukos Corp (GKOS) to its portfolio

Glaukos Corp (GKOS) : Regis Management Co added new position in Glaukos Corp during the most recent quarter end. The investment management firm now holds 80,703 shares of Glaukos Corp which is valued at $2,655,129 , the company said in a statement filed on Aug 3, 2016 with the SEC.Glaukos Corp makes up approximately 0.52% of Regis Management Co’s portfolio.

Other Hedge Funds, Including , Cadence Capital Management added GKOS to its portfolio by purchasing 9,660 company shares during the most recent quarter which is valued at $317,814. Glaukos Corp makes up approx 0.02% of Cadence Capital Management’s portfolio. Inspirion Wealth Advisors added GKOS to its portfolio by purchasing 9,902 company shares during the most recent quarter which is valued at $325,776. Glaukos Corp makes up approx 0.21% of Inspirion Wealth Advisors’s portfolio. Achievement Holdings sold out all of its stake in GKOS during the most recent quarter. The investment firm sold 24,500 shares of GKOS which is valued $859,460. Simplex Trading added GKOS to its portfolio by purchasing 58 company shares during the most recent quarter which is valued at $1,905.Bnp Paribas Arbitrage Sa boosted its stake in GKOS in the latest quarter, The investment management firm added 537 additional shares and now holds a total of 718 shares of Glaukos Corp which is valued at $20,994.

Glaukos Corp opened for trading at $33.04 and hit $33.65 on the upside on Monday, eventually ending the session at $33.63, with a gain of 1.79% or 0.59 points. The heightened volatility saw the trading volume jump to 5,06,928 shares. Company has a market cap of $1,111 M.

On the company’s financial health, Glaukos Corp reported $0.06 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Aug 1, 2016. Analyst had a consensus of $-0.04. The company had revenue of $28.60 million for the quarter, compared to analysts expectations of $24.45 million. The company’s revenue was up 60.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-1.30 EPS.

Many Wall Street Analysts have commented on Glaukos Corp. Company shares were Reiterated by Cantor Fitzgerald on Aug 2, 2016 to “Buy”, Firm has raised the Price Target to $ 41 from a previous price target of $35 .Cantor Fitzgerald Initiated Glaukos Corp on Jun 3, 2016 to “Buy”, Price Target of the shares are set at $35.

Glaukos Corporation (Glaukos) is an ophthalmic medical technology company. The Company is engaged in the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent an MIGS device measuring one millimeter long and 0.33 millimeter wide. MIGS procedures involve the insertion of a micro-scale device from within the eye’s anterior chamber through a small corneal incision. Glaukos is also engaged in developing a portfolio of micro-scale injectable therapies including three pipeline products namely the iStent Inject the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is an implant that is designed to provide a sustained release of a prostaglandin drug to lower intraocular pressure in glaucoma patients.

Leave a Reply

Glaukos Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Glaukos Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.